Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | TTK | P33981 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344425 | 0.87 | NLRP3 (0.56) | NLRP3TTKTHRBMAPTLMNA | |
| SCHEMBL3350261 | 0.82 | CSNK2A1 (0.42) | MAPTLMNAKDM4ERAB9AGAA | |
| SCHEMBL23581766 | 0.82 | NLRP3 (0.56) | NLRP3TTKMAPTLMNAKDM4E | |
| SCHEMBL13304907 | 0.80 | TTK (0.68) | NLRP3TTKTHRBLMNAKDM4E | |
| SCHEMBL31436857 | 0.77 | NLRP3 (0.55) | NLRP3TTKMAPTLMNAKDM4E | |
| SCHEMBL21708015 | 0.77 | MAPT (0.67) | THRBMAPTLMNAKDM4ENPSR1 | |
| SCHEMBL23581727 | 0.76 | NLRP3 (0.63) | NLRP3TTKKDM4ECYP1A2 | |
| SCHEMBL553902 | 0.75 | NLRP3 (0.56) | NLRP3TTKMAPTLMNAKDM4E | |
| SCHEMBL3045442 | 0.73 | NLRP3 (0.56) | NLRP3TTKTHRBMAPTRAB9A | |
| SCHEMBL10550202 | 0.73 | THRB (0.53) | THRBMAPK14MAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160397-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160397-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | DGAT1, ACAT1, DGAT2 | NLRP3 2346/4885TTK 1998/4885THRB 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.